

## Product datasheet for **TL314110V**

### CD14 Human shRNA Lentiviral Particle (Locus ID 929)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	CD14 Human shRNA Lentiviral Particle (Locus ID 929)
Locus ID:	929
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CD14 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<u><a href="#">NM_000591</a></u> , <u><a href="#">NM_001040021</a></u> , <u><a href="#">NM_001174104</a></u> , <u><a href="#">NM_001174105</a></u> , <u><a href="#">NM_000591.1</a></u> , <u><a href="#">NM_000591.2</a></u> , <u><a href="#">NM_000591.3</a></u> , <u><a href="#">NM_001040021.1</a></u> , <u><a href="#">NM_001040021.2</a></u> , <u><a href="#">NM_001174104.1</a></u> , <u><a href="#">NM_001174105.1</a></u> , <u><a href="#">BC010507</a></u> , <u><a href="#">NM_001040021.3</a></u> , <u><a href="#">NM_000591.4</a></u> , <u><a href="#">NM_001174105.2</a></u>
UniProt ID:	<u><a href="#">P08571</a></u>
Summary:	The protein encoded by this gene is a surface antigen that is preferentially expressed on monocytes/macrophages. It cooperates with other proteins to mediate the innate immune response to bacterial lipopolysaccharide, and to viruses. This gene has been identified as a target candidate in the treatment of SARS-CoV-2-infected patients to potentially lessen or inhibit a severe inflammatory response. Alternative splicing results in multiple transcript variants encoding the same protein. [provided by RefSeq, Aug 2020]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).